Navigation Links
New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes
Date:4/23/2010

PARSIPPANY, N.J., April 23 /PRNewswire/ -- Results of a new study showed that Welchol® (colesevelam HCl) 3.75 g/d significantly improved lipid and glycemic measures in patients with high LDL cholesterol and prediabetes (impaired fasting glucose and/or impaired glucose tolerance).  The randomized, placebo-controlled, double-blind study was presented today at the American Association of Clinical Endocrinologists (AACE) 19th Annual Meeting and Clinical Congress in Boston.(1)  These data are consistent with previous studies that have shown Welchol to be safe and effective in lowering A1C, fasting plasma glucose and low-density lipoprotein cholesterol (LDL-C) in adult patients with type 2 diabetes.(2)

"These new findings are important because they provide valuable information on the effects of Welchol to significantly reduce LDL cholesterol, fasting plasma glucose, and A1C levels in patients at high risk for developing type 2 diabetes," said Yehuda Handelsman, MD, FACP, FACE, Medical Director of the Metabolic Institute of America in Tarzana, Calif. and investigator of the study.  "The evaluation of Welchol in this high risk population underscores recent guidelines established by AACE, which recommended physicians target and treat underlying disorders such as high cholesterol and elevated glucose levels in people with prediabetes."(3)

Approximately 57 million adults in the U.S. have impaired fasting glucose and/or impaired glucose tolerance, which puts them at a three to 10 times higher risk of developing type 2 diabetes and a 1.5 times greater risk of cardiovascular disease.(3,4,5)  A recent position statement from the American Diabetes Association (ADA) stated that individuals with an A1C level of
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
2. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
3. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
4. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
5. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
6. Tobiras Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
7. NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines
10. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
11. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015 Thirty-six ... percent seek help. During May – National Hearing Month ... loss could be missing out on the sounds of ... the trees. To ensure that you won,t ... that color our world, Oticon, Inc. offers practical advice: ...
(Date:5/4/2015)... 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... roles, appointing  Donna M. Hughes, as Senior Vice President, ... Senior Vice President, Chief Compliance Officer. Both Ms. Hughes ... Chief Executive Officer, Fred Wilkinson . ... the Impax team," said Fred Wilkinson , President ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:It's Better Hearing Month 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... Jan. 3, 2011 The MED Group, a Managed ... of www.medicaresuppliersnetwork.com .  The website was created to ... such as physician offices, about competitive bidding and how ... program. The Centers for Medicare and Medicaid ...
... Boston Scientific Corporation (NYSE: BSX ) ... its Neurovascular business to Stryker Corporation.  The sale price ... at closing (including an upfront payment of $1.376 billion, ... of the next-generation Target™ Detachable Coils, and $24 million ...
Cached Medicine Technology:New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Ohio 2New Program for Medicare Beneficiaries Will Mean Major Changes Effective January 1, 2011 - Ohio 3Boston Scientific Completes Sale of Neurovascular Business 2Boston Scientific Completes Sale of Neurovascular Business 3Boston Scientific Completes Sale of Neurovascular Business 4
(Date:5/4/2015)... City, NY (PRWEB) May 05, 2015 ... honors Patti Hommes as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... recognize Patti with this important honor,” says NAPW President ...
(Date:5/4/2015)... 04, 2015 Every Friday afternoon at ... located in Southwest Michigan, patients and staff gather in ... graduating the rehabilitation program and to gain encouragement and ... , One by one, those patients who have ... accept their certificates and to share a bit about ...
(Date:5/4/2015)... HHT is a rare but cruel and ... can have seemingly mild symptoms like frequent nosebleeds, it ... Hemorrhagic Telangiectasia (HHT) is a hereditary disorder resulting in ... connections between an artery and a vein. These abnormalities ... may also be present in the lungs, brain and ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... “ LiveSchool ” was featured on NewsWatch ... look at the latest and coolest applications on the ... host of AppWatch and technology expert, conducted the app ... teachers to reward students with good behavior. , Positive ... the classroom. And the good people at LiveSchool ...
Breaking Medicine News(10 mins):Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2
... According to the National Cancer,Institute, 1 in 8 ... 40,000 women will die of breast cancer in the ... lung cancer as the leading cause of cancer,deaths in ... Carole Aydell has heard,countless excuses for why women refuse ...
... (NYSE: SRZ ) today announced the appointment of ... March 19, 2008., Prior to joining Sunrise, Mr. ... The Mills Corporation, where he oversaw the eventual sale ... May 2007. Previously, he,founded and was Chief Executive Officer ...
... IT in, Support of Federal Agencies and Healthcare Providers Will ... ... CHURCH, Va., March 20 Harris,Corporation (NYSE: HRS ), ... contract by the U.S. Department of,Health and Human Services to ...
... phone survey conducted among 1,000 allergy sufferers, 1,000 consumers ... that beyond the sneezing, sniffling and watery eyes, allergies ... mood and self-perceptions. , According to Attitudes ... allergies affect their mood. 51 percent of sufferers ...
... Certified asthma & allergy friendly(TM) by the Asthma, and Allergy Foundation ... ... to More Consumers, ENGLEWOOD CLIFFS, N.J., March 20 ... help those suffering from,common household allergies, LG Electronics today announced the ...
... GREENSBORO, N.C., March 20 Acting U.S.,Surgeon General Rear ... adolescent overweight and obesity to members of the Society ... in Greensboro,NC next week. Dr. Galson will speak on ... to nearly 500 SAM members. In early March Dr. ...
Cached Medicine News:Health News:Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Women's Negative Attitudes Toward Mammograms 2Health News:Sunrise Senior Living Names Mark Ordan Chief Investment and Administrative Officer 2Health News:Sunrise Senior Living Names Mark Ordan Chief Investment and Administrative Officer 3Health News:Harris Corporation Awarded Contract to Develop National Health Information Exchange Gateway for Sharing Patient Records 2Health News:New survey shows allergies dramatically impact sufferers' moods and how they feel about themselves 2Health News:LG Electronics Debuts Unique Allergen-Reducing Steam Washer/Dryer Combo 2Health News:LG Electronics Debuts Unique Allergen-Reducing Steam Washer/Dryer Combo 3Health News:LG Electronics Debuts Unique Allergen-Reducing Steam Washer/Dryer Combo 4Health News:Acting U.S. Surgeon General to Speak to Society for Adolescent Medicine on Prevention of Adolescent Overweight and Obesity 2Health News:Acting U.S. Surgeon General to Speak to Society for Adolescent Medicine on Prevention of Adolescent Overweight and Obesity 3
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
The design of the new ChloraPrep swabstick applicator provides significant improvement in performance over traditional swabsticks....
... Swabsticks are packaged in easy open, single-use ... saturated with precisely the correct amount of ... the safest possible product for the patient. ... an excellent combination of ethyl alcohol and ...
... provides 5% povidone-iodine solution ... It delivers a microbicidal ... tender to touch. It ... indicated whenever effective microbicidal ...
Medicine Products: